Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix-Hexa primary and booster immune response study with randomized MenC vaccine comparison in UK infants
ISRCTN27374886Phase 4Completed
- Sponsor
- Health Protection Agency (UK)
- Start
- Jun 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, open-label trial in meningococcal disease, Haemophilus influenzae type b disease (Hib), pneumococcal disease and 5 more comparing Infanrix-Hexa + PCV13 + NeisVacC, Infanrix-Hexa + PCV13 + Menjugate and Infanrix-Hexa + PCV13 + Menitorix (3 arms). Primary endpoints: Hib antibody concentrations after primary immunization, MenC-specific antibody titres after primary immunization and 1 more. Started Jun 2013; status: completed.
02
Drugs
Infanrix Hexapneumococcal 13-valent conjugate vaccineMeningococcal group C polysaccharide conjugate vaccineHib-MenC-TT
03
Conditions
meningococcal diseaseHaemophilus influenzae type b disease (Hib)pneumococcal diseasediphtheriaTetanus
Beyond the preview
Go deeper on ISRCTN27374886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN27374886.